Blockchain Registration Transaction Record

GeoVax's Gedeptin Shows Promise to Boost Checkpoint Inhibitors in Resistant Tumors

GeoVax's Gedeptin therapy enhances checkpoint inhibitor responses in resistant metastatic solid tumors, as published in JCI Insight. Learn how intratumoral GDEPT activates systemic anti-tumor immunity.

This news matters because it addresses a critical challenge in oncology: the limited effectiveness of immune checkpoint inhibitors against many solid tumors. GeoVax's Gedeptin therapy could transform treatment by turning resistant tumors into responsive ones, potentially benefiting millions of cancer patients who currently have limited options. The ability to activate systemic immunity from localized injections also suggests a more tolerable approach, reducing side effects while expanding therapeutic reach.